UCLA perform new transcarotid stenting with dynamic flow reversal procedure

262

Physicians at Ronald Reagan UCLA Medical Center are the first on the West Coast to perform a new, less-invasive procedure that is part of a clinical trial to help clear plaque from the carotid arteries, according to a release. The procedure took place on 28 March.

Current treatment options include traditional open surgery to clean out the carotid artery and a minimally-invasive alternative that uses a stent to keep the artery open. However, each option has some limitations. Traditional surgery involves a large incision along the neck and carries risk of surgical complications. The stent procedure is less invasive, but some studies have shown that it causes a higher risk of stroke than the surgical procedure.

Now, a new technique and device system is being tested called transcarotid stenting with dynamic flow reversal, or the Silk Road Procedure. It, according to the release, allows physicians to deliver a stent directly into the carotid artery from the neck, offering a shorter, potentially safer route than the usual method of guiding a stent from an artery in the groin, which carries a risk of plaque dislodging.

A unique aspect of the new system is the ability to temporarily divert blood flow away from the plaque during the procedure to help ensure that the patient’s brain is fully protected from plaque debris at all times. Physicians redirect blood flow from the carotid artery where the team is working into tubing set up outside the body and then back into the body via the femoral vein located near the groin.

“We’re always seeking new options for patients with the ultimate goal of treating these carotid artery blockages with the least procedural risk,” said Wesley Moore, UCLA study investigator and professor emeritus of vascular surgery, David Geffen School of Medicine at UCLA, USA. “We look forward to contributing to this important research.”

Ronald Reagan UCLA Medical Center is one of 25 centres around the world participating in the study—the ROADSTER trial, designed for high surgical risk patients who may be older or have especially narrowed arteries.

The study is funded by Silk Road Medical, developers of the transcarotid stenting with dynamic flow reversal system.